Assessment of HER2 status in extramammary Paget disease and its implication for disitamab vedotin,a novel humanized anti-HER2 antibody-drug conjugate therapy  

作　　者：Jia Jia Lili Mao Jing Lin Wenyu Li Pei Yuan Lei Guo Jie Dai Caili Li Xue Bai Zhongwu Li Yu Chen Jun Guo Jianming Ying Lu Si 

机构地区：[1]State Key Laboratory of Molecular Oncology,Department of Pathology,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing,100021,China [2]Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing),Department of Melanoma and Sarcoma,Peking University Cancer Hospital&Institute,Beijing,100142,China [3]Department of Medical Oncology,Clinical Oncology School of Fujian Medical University,Fujian Cancer Hospital,Fuzhou,350014,China [4]Department of Pathology,Peking University Cancer Hospital&Institute,Beijing,100142,China

出　　处：《Frontiers of Medicine》2024年第3期565-569,共5页医学前沿（英文版）

基　　金：supported by Beijing Medical Award Foundation(No.YXJL-2020-0889-0106);Beijing Municipal Administration of Hospitals’Ascent Plan(No.DFL20220901);Beijing Xisike Clinical Oncology Research Foundation(Nos.Y-Roche2019/2-0076 and Y-SY201901-0270).

摘　　要：Dear Editor,Extramammary Paget disease(EMPD)is a rare adenocarcinoma that originates in the apocrine gland-rich skin and usually affects the perineal skin(primary EMPD)or represents the intraepithelial spread of an underlying visceral carcinoma(secondary EMPD).Approximately half of EMPD cases are confined to the epidermis,which was defined as intraepithelial EMPD.

关 键 词：PAGET HER2 ADENOCARCINOMA 

分 类 号：R737.9[医药卫生—肿瘤]